{
    "title": "GlaxoSmithKline sees better signs for lung drugs after tough 2014",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2939479/GlaxoSmithKline-sees-better-signs-lung-drugs-tough-2014.html",
    "date": "2015-02-04",
    "keywords": [
        "year",
        "market",
        "share",
        "novartis",
        "respiratory",
        "viiv",
        "company",
        "half",
        "growth",
        "glaxosmithkline",
        "lung",
        "gmt",
        "executive",
        "advair",
        "healthcare",
        "drugmaker",
        "deal",
        "core",
        "percent",
        "ipo",
        "dividend",
        "email",
        "ben",
        "hirschlerlondon",
        "medicine",
        "demand",
        "drug",
        "drugmakergsk",
        "asset",
        "swap",
        "value",
        "hiv",
        "unit",
        "matterchief",
        "andrew",
        "pressure",
        "challenging",
        "performance",
        "wednesdaywitty",
        "gsk",
        "japan",
        "breo",
        "anoro",
        "call",
        "increase",
        "rest",
        "growththe",
        "dealgsk",
        "cancer",
        "consumer",
        "health",
        "venture",
        "transaction",
        "quarter",
        "measure",
        "forecast",
        "pence",
        "thomson",
        "cost",
        "tax",
        "rate",
        "companys",
        "gmtif",
        "franchise",
        "horizon",
        "return",
        "bernenberg",
        "bank",
        "stock",
        "business",
        "flexibility",
        "operationsthe",
        "october",
        "offering",
        "minority",
        "stake",
        "month",
        "model",
        "level",
        "hardcastle",
        "david",
        "goodman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}